After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Pfizer's 7.5% dividend yield, strong R&D innovation, and defensive market position make it a smart buy. Read here for an ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...

Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

The global interferons market is on a steady growth trajectory, with its valuation projected to surge from USD 9.4 billion in 2022 to USD 13.8 billion by 2032. According to a recent report by Future ...

COVID infection has been linked to higher risk of autoimmune disorders, including rheumatoid arthritis and type 1 diabetes.